Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1]
It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.[2]
- Market Cap ₹ 1,08,125 Cr.
- Current Price ₹ 3,195
- High / Low ₹ 3,257 / 1,771
- Stock P/E 64.6
- Book Value ₹ 203
- Dividend Yield 0.88 %
- ROCE 23.2 %
- ROE 24.2 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company has been maintaining a healthy dividend payout of 73.8%
- Company's working capital requirements have reduced from 72.1 days to 53.1 days
Cons
- Stock is trading at 15.8 times its book value
- The company has delivered a poor sales growth of 6.93% over past five years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3,203 | 4,172 | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 10,996 | |
2,506 | 3,216 | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,515 | |
Operating Profit | 697 | 955 | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,481 |
OPM % | 22% | 23% | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% |
1 | 34 | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | 45 | 146 | 136 | |
Interest | 34 | 59 | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 326 |
Depreciation | 83 | 87 | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 814 |
Profit before tax | 582 | 844 | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,477 |
Tax % | 25% | 21% | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | 33% | 30% | |
435 | 664 | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,735 | |
EPS in Rs | 12.79 | 19.62 | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 51.27 |
Dividend Payout % | 45% | 25% | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% | 60% | 57% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 7% |
3 Years: | 10% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 22% |
3 Years: | 8% |
TTM: | 32% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 31% |
3 Years: | 27% |
1 Year: | 61% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 21% |
3 Years: | 21% |
Last Year: | 24% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 42 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 |
Reserves | 1,380 | 1,818 | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 |
693 | 1,132 | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | |
1,638 | 1,988 | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | |
Total Liabilities | 3,753 | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 |
820 | 875 | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | |
CWIP | 285 | 534 | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 |
Investments | 60 | 186 | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 |
2,587 | 3,427 | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | |
Total Assets | 3,753 | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
153 | 599 | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 | |
-247 | -418 | -2,113 | -869 | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 | |
20 | 86 | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 | |
Net Cash Flow | -73 | 268 | -90 | 437 | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 78 | 96 | 125 | 79 | 60 | 77 | 68 | 76 | 69 | 70 | 74 | 63 |
Inventory Days | 364 | 297 | 275 | 314 | 318 | 429 | 318 | 362 | 456 | 368 | 298 | 310 |
Days Payable | 421 | 421 | 472 | 523 | 356 | 447 | 345 | 345 | 351 | 250 | 224 | 284 |
Cash Conversion Cycle | 22 | -28 | -71 | -130 | 21 | 59 | 42 | 93 | 174 | 188 | 147 | 89 |
Working Capital Days | 33 | 42 | 54 | -1 | 28 | 20 | -17 | -2 | 82 | 89 | 74 | 53 |
ROCE % | 33% | 35% | 27% | 48% | 19% | 13% | 13% | 15% | 17% | 19% | 20% | 23% |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 2d
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
23 Jul - Audio Recording of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 2024
- Announcement under Regulation 30 (LODR)-Change in Management 23 Jul
- Announcement under Regulation 30 (LODR)-Cessation 23 Jul
- Shareholder Meeting / Postal Ballot-Outcome of AGM 23 Jul
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
May 2024TranscriptPPT
-
Feb 2024TranscriptPPT
-
Aug 2023TranscriptPPT
-
May 2023TranscriptPPT
-
Sep 2022TranscriptNotesPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
May 2018TranscriptNotesPPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Oct 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
May 2016TranscriptPPT
Product Offerings
The company manufactures pharmaceutical products under various dosage forms such as oral solids, oral liquids, topicals, suppositories, Human insulin and synthetic APIs. API manufacturing is predominantly aimed at captive consumption.[1]